275 related articles for article (PubMed ID: 30638863)
1. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
[TBL] [Abstract][Full Text] [Related]
2. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.
Sloan SE; Szretter KJ; Sundaresh B; Narayan KM; Smith PF; Skurnik D; Bedard S; Trevejo JM; Oldach D; Shriver Z
Antiviral Res; 2020 Dec; 184():104763. PubMed ID: 32151645
[TBL] [Abstract][Full Text] [Related]
3. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks.
Wollacott AM; Boni MF; Szretter KJ; Sloan SE; Yousofshahi M; Viswanathan K; Bedard S; Hay CA; Smith PF; Shriver Z; Trevejo JM
EBioMedicine; 2016 Mar; 5():147-55. PubMed ID: 27077121
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
McBride JM; Lim JJ; Burgess T; Deng R; Derby MA; Maia M; Horn P; Siddiqui O; Sheinson D; Chen-Harris H; Newton EM; Fillos D; Nazzal D; Rosenberger CM; Ohlson MB; Lambkin-Williams R; Fathi H; Harris JM; Tavel JA
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807912
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
6. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
Trevejo JM; Asmal M; Vingerhoets J; Polo R; Robertson S; Jiang Y; Kieffer TL; Leopold L
Antivir Ther; 2018; 23(4):335-344. PubMed ID: 29244026
[TBL] [Abstract][Full Text] [Related]
7. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
Finberg RW; Lanno R; Anderson D; Fleischhackl R; van Duijnhoven W; Kauffman RS; Kosoglou T; Vingerhoets J; Leopold L
J Infect Dis; 2019 Mar; 219(7):1026-1034. PubMed ID: 30428049
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
Ali SO; Takas T; Nyborg A; Shoemaker K; Kallewaard NL; Chiong R; Dubovsky F; Mallory RM
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150460
[TBL] [Abstract][Full Text] [Related]
9. Assessment of CD8
Evans TG; Castellino F; Kowalik Dobczyk M; Tucker G; Walley AM; Van Leuven K; Klein J; Rutkowski K; Ellis C; Eagling-Vose E; Treanor J; van Baalen C; Filkov E; Laurent C; Thacker J; Asher J; Donabedian A
Lancet Microbe; 2024 Jul; 5(7):645-654. PubMed ID: 38729196
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Yang Z; Li Z; Zhan Y; Lin Z; Fang Z; Xu X; Lin L; Li H; Lin Z; Kang C; Liang J; Liang S; Li Y; Li S; Yang X; Ye F; Zhong N;
Lancet Infect Dis; 2024 May; 24(5):535-545. PubMed ID: 38330975
[TBL] [Abstract][Full Text] [Related]
11. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
Hayden FG; Treanor JJ; Fritz RS; Lobo M; Betts RF; Miller M; Kinnersley N; Mills RG; Ward P; Straus SE
JAMA; 1999 Oct; 282(13):1240-6. PubMed ID: 10517426
[TBL] [Abstract][Full Text] [Related]
12. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
[TBL] [Abstract][Full Text] [Related]
14. [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
Geppe NA; Kondiurina EG; Galustian AN; Pak TE; Bal'tserovich NB; Zhiglinskaia OV; Kamaev AV; Lazareva SG; Laléko SL; Mel'nikova IM; Perminova OA; Sabitov AU
Antibiot Khimioter; 2014; 59(5-6):6-14. PubMed ID: 25552038
[TBL] [Abstract][Full Text] [Related]
15. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Davey RT; Fernández-Cruz E; Markowitz N; Pett S; Babiker AG; Wentworth D; Khurana S; Engen N; Gordin F; Jain MK; Kan V; Polizzotto MN; Riska P; Ruxrungtham K; Temesgen Z; Lundgren J; Beigel JH; Lane HC; Neaton JD;
Lancet Respir Med; 2019 Nov; 7(11):951-963. PubMed ID: 31582358
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.
Hayden FG; Treanor JJ; Betts RF; Lobo M; Esinhart JD; Hussey EK
JAMA; 1996 Jan 24-31; 275(4):295-9. PubMed ID: 8544269
[TBL] [Abstract][Full Text] [Related]
17. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
Leyva-Grado VH; Tan GS; Leon PE; Yondola M; Palese P
Antimicrob Agents Chemother; 2015 Jul; 59(7):4162-72. PubMed ID: 25941218
[TBL] [Abstract][Full Text] [Related]
18. Intravenous peramivir for treatment of influenza in hospitalized patients.
Ison MG; Fraiz J; Heller B; Jauregui L; Mills G; O'Riordan W; O'Neil B; Playford EG; Rolf JD; Sada-Diaz E; Elder J; Collis P; Hernandez JE; Sheridan WP
Antivir Ther; 2014; 19(4):349-61. PubMed ID: 23985625
[TBL] [Abstract][Full Text] [Related]
19. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials.
Whitley R; Laughlin A; Carson S; Mitha E; Tellier G; Stich M; Elder J; Alexander WJ; Dobo S; Collis P; Sheridan WP
Antivir Ther; 2015; 20(7):709-19. PubMed ID: 25318121
[TBL] [Abstract][Full Text] [Related]
20. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
